請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/5462
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 許秉寧(Ping-Ning Hsu) | |
dc.contributor.author | Horng-Tay Tzeng | en |
dc.contributor.author | 曾鴻泰 | zh_TW |
dc.date.accessioned | 2021-05-15T17:59:35Z | - |
dc.date.available | 2017-03-17 | |
dc.date.available | 2021-05-15T17:59:35Z | - |
dc.date.copyright | 2014-03-17 | |
dc.date.issued | 2014 | |
dc.date.submitted | 2014-02-10 | |
dc.identifier.citation | Barber, D.L., Wherry, E.J., Masopust, D., Zhu, B., Allison, J.P., Sharpe, A.H., Freeman, G.J., and Ahmed, R. (2006). Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 439, 682-687.
Barton, G.M. (2007). Viral recognition by Toll-like receptors. Semin Immunol 19, 33-40. Bauer, T., Sprinzl, M., and Protzer, U. (2011a). Immune control of hepatitis B virus. Dig Dis 29, 423-433. Bauer, T., Sprinzl, M., and Protzer, U. (2011b). Immune Control of Hepatitis B Virus. Digestive Diseases 29, 423-433. Ben-Ari, Z., Mor, E., Papo, O., Kfir, B., Sulkes, J., Tambur, A.R., Tur-Kaspa, R., and Klein, T. (2003). Cytokine gene polymorphisms in patients infected with hepatitis B virus. Am J Gastroenterol 98, 144-150. Bertoletti, A., and Ferrari, C. (2012). Innate and adaptive immune responses in chronic hepatitis B virus infections: towards restoration of immune control of viral infection. Gut 61, 1754-1764. Bertoletti, A., and Ferrari, C. (2013). Innate and adaptive immune responses in chronic hepatitis B virus infections: towards restoration of immune control of viral infection. Postgrad Med J 89, 294-304. Bertoletti, A., Maini, M.K., and Ferrari, C. (2010). The host-pathogen interaction during HBV infection: immunological controversies. Antivir Ther 15 Suppl 3, 15-24. Billerbeck, E., Kang, Y.H., Walker, L., Lockstone, H., Grafmueller, S., Fleming, V., Flint, J., Willberg, C.B., Bengsch, B., Seigel, B., et al. (2010). Analysis of CD161 expression on human CD8+ T cells defines a distinct functional subset with tissue-homing properties. Proc Natl Acad Sci U S A 107, 3006-3011. Blanchet, M., and Sureau, C. (2007). Infectivity determinants of the hepatitis B virus pre-S domain are confined to the N-terminal 75 amino acid residues. J Virol 81, 5841-5849. Boettler, T., Panther, E., Bengsch, B., Nazarova, N., Spangenberg, H.C., Blum, H.E., and Thimme, R. (2006). Expression of the interleukin-7 receptor alpha chain (CD127) on virus-specific CD8+ T cells identifies functionally and phenotypically defined memory T cells during acute resolving hepatitis B virus infection. J Virol 80, 3532-3540. Boni, C., Fisicaro, P., Valdatta, C., Amadei, B., Di Vincenzo, P., Giuberti, T., Laccabue, D., Zerbini, A., Cavalli, A., Missale, G., et al. (2007). Characterization of hepatitis B virus (HBV)-specific T-cell dysfunction in chronic HBV infection. J Virol 81, 4215-4225. Bouchard, M.J., and Schneider, R.J. (2004). The enigmatic X gene of hepatitis B virus. J Virol 78, 12725-12734. Bramson, J.L., Graham, F.L., and Gauldie, J. (1995). The use of adenoviral vectors for gene therapy and gene transfer in vivo. Curr Opin Biotechnol 6, 590-595. Breous, E., Somanathan, S., Vandenberghe, L.H., and Wilson, J.M. (2009). Hepatic regulatory T cells and Kupffer cells are crucial mediators of systemic T cell tolerance to antigens targeting murine liver. Hepatology 50, 612-621. Breous, E., Somanathan, S., and Wilson, J.M. (2010). BALB/c mice show impaired hepatic tolerogenic response following AAV gene transfer to the liver. Mol Ther 18, 766-774. Brunda, M.J., and Rosenbaum, D. (1984). Modulation of murine natural killer cell activity in vitro and in vivo by recombinant human interferons. Cancer Res 44, 597-601. Chen, L. (2004). Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity. Nat Rev Immunol 4, 336-347. Chen, S.H., Wu, H.L., Kao, J.H., and Hwang, L.H. (2012). Persistent hepatitis B viral replication in a FVB/N mouse model: impact of host and viral factors. PLoS One 7, e36984. Chen, Z., Cheng, Y., Xu, Y., Liao, J., Zhang, X., Hu, Y., Zhang, Q., Wang, J., Zhang, Z., Shen, F., and Yuan, Z. (2008). Expression profiles and function of Toll-like receptors 2 and 4 in peripheral blood mononuclear cells of chronic hepatitis B patients. Clin Immunol 128, 400-408. Chintakuntlawar, A.V., Zhou, X., Rajaiya, J., and Chodosh, J. (2010). Viral capsid is a pathogen-associated molecular pattern in adenovirus keratitis. PLoS Pathog 6, e1000841. Chisari, F.V., and Ferrari, C. (1995). Hepatitis B virus immunopathogenesis. Annu Rev Immunol 13, 29-60. Chisari, F.V., Pinkert, C.A., Milich, D.R., Filippi, P., McLachlan, A., Palmiter, R.D., and Brinster, R.L. (1985). A transgenic mouse model of the chronic hepatitis B surface antigen carrier state. Science 230, 1157-1160. Crispe, I.N. (2011). Liver antigen-presenting cells. J Hepatol 54, 357-365. Dandri, M., Burda, M.R., Torok, E., Pollok, J.M., Iwanska, A., Sommer, G., Rogiers, X., Rogler, C.E., Gupta, S., Will, H., et al. (2001). Repopulation of mouse liver with human hepatocytes and in vivo infection with hepatitis B virus. Hepatology 33, 981-988. Day, C.L., Kaufmann, D.E., Kiepiela, P., Brown, J.A., Moodley, E.S., Reddy, S., Mackey, E.W., Miller, J.D., Leslie, A.J., DePierres, C., et al. (2006). PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature 443, 350-354. Dunn, C., Brunetto, M., Reynolds, G., Christophides, T., Kennedy, P.T., Lampertico, P., Das, A., Lopes, A.R., Borrow, P., Williams, K., et al. (2007). Cytokines induced during chronic hepatitis B virus infection promote a pathway for NK cell-mediated liver damage. J Exp Med 204, 667-680. Dunn, C., Peppa, D., Khanna, P., Nebbia, G., Jones, M., Brendish, N., Lascar, R.M., Brown, D., Gilson, R.J., Tedder, R.J., et al. (2009). Temporal analysis of early immune responses in patients with acute hepatitis B virus infection. Gastroenterology 137, 1289-1300. Durantel, D., and Zoulim, F. (2009). Innate response to hepatitis B virus infection: observations challenging the concept of a stealth virus. Hepatology 50, 1692-1695. Ebert, G., Poeck, H., Lucifora, J., Baschuk, N., Esser, K., Esposito, I., Hartmann, G., and Protzer, U. (2011). 5' Triphosphorylated small interfering RNAs control replication of hepatitis B virus and induce an interferon response in human liver cells and mice. Gastroenterology 141, 696-706, 706 e691-693. Feng, I.C., Koay, L.B., Sheu, M.J., Kuo, H.T., Sun, C.S., Lee, C., Chuang, W.L., Liao, S.K., Wang, S.L., Tang, L.Y., et al. (2007). HBcAg-specific CD4+CD25+ regulatory T cells modulate immune tolerance and acute exacerbation on the natural history of chronic hepatitis B virus infection. J Biomed Sci 14, 43-57. Fisicaro, P., Valdatta, C., Boni, C., Massari, M., Mori, C., Zerbini, A., Orlandini, A., Sacchelli, L., Missale, G., and Ferrari, C. (2009). Early kinetics of innate and adaptive immune responses during hepatitis B virus infection. Gut 58, 974-982. Fisicaro, P., Valdatta, C., Massari, M., Loggi, E., Biasini, E., Sacchelli, L., Cavallo, M.C., Silini, E.M., Andreone, P., Missale, G., and Ferrari, C. Antiviral intrahepatic T-cell responses can be restored by blocking programmed death-1 pathway in chronic hepatitis B. Gastroenterology 138, 682-693, 693 e681-684. Fisicaro, P., Valdatta, C., Massari, M., Loggi, E., Biasini, E., Sacchelli, L., Cavallo, M.C., Silini, E.M., Andreone, P., Missale, G., and Ferrari, C. (2010). Antiviral intrahepatic T-cell responses can be restored by blocking programmed death-1 pathway in chronic hepatitis B. Gastroenterology 138, 682-693, 693 e681-684. Gehring, A.J., Koh, S., Chia, A., Paramasivam, K., Chew, V.S., Ho, Z.Z., Lee, K.H., Maini, M.K., Madhavan, K., Lim, S.G., and Bertoletti, A. (2011). Licensing virus-specific T cells to secrete the neutrophil attracting chemokine CXCL-8 during hepatitis B virus infection. PLoS One 6, e23330. Gilles, P.N., Fey, G., and Chisari, F.V. (1992). Tumor necrosis factor alpha negatively regulates hepatitis B virus gene expression in transgenic mice. J Virol 66, 3955-3960. Golden-Mason, L., Palmer, B., Klarquist, J., Mengshol, J.A., Castelblanco, N., and Rosen, H.R. (2007). Upregulation of PD-1 expression on circulating and intrahepatic hepatitis C virus-specific CD8+ T cells associated with reversible immune dysfunction. J Virol 81, 9249-9258. Goncalves, M.A. (2005). Adeno-associated virus: from defective virus to effective vector. Virol J 2, 43. Guidotti, L.G., Ishikawa, T., Hobbs, M.V., Matzke, B., Schreiber, R., and Chisari, F.V. (1996). Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes. Immunity 4, 25-36. Guidotti, L.G., Rochford, R., Chung, J., Shapiro, M., Purcell, R., and Chisari, F.V. (1999). Viral clearance without destruction of infected cells during acute HBV infection. Science 284, 825-829. Guo, H., Jiang, D., Ma, D., Chang, J., Dougherty, A.M., Cuconati, A., Block, T.M., and Guo, J.T. (2009). Activation of pattern recognition receptor-mediated innate immunity inhibits the replication of hepatitis B virus in human hepatocyte-derived cells. J Virol 83, 847-858. Guy, C.S., Mulrooney-Cousins, P.M., Churchill, N.D., and Michalak, T.I. (2008). Intrahepatic expression of genes affiliated with innate and adaptive immune responses immediately after invasion and during acute infection with woodchuck hepadnavirus. J Virol 82, 8579-8591. Ha, S.J., Mueller, S.N., Wherry, E.J., Barber, D.L., Aubert, R.D., Sharpe, A.H., Freeman, G.J., and Ahmed, R. (2008). Enhancing therapeutic vaccination by blocking PD-1-mediated inhibitory signals during chronic infection. J Exp Med 205, 543-555. Han, Q., Zhang, C., Zhang, J., and Tian, Z. (2011). Reversal of hepatitis B virus-induced immune tolerance by an immunostimulatory 3p-HBx-siRNAs in a retinoic acid inducible gene I-dependent manner. Hepatology 54, 1179-1189. Hartman, Z.C., Appledorn, D.M., and Amalfitano, A. (2008). Adenovirus vector induced innate immune responses: impact upon efficacy and toxicity in gene therapy and vaccine applications. Virus Res 132, 1-14. Hartman, Z.C., Kiang, A., Everett, R.S., Serra, D., Yang, X.Y., Clay, T.M., and Amalfitano, A. (2007). Adenovirus infection triggers a rapid, MyD88-regulated transcriptome response critical to acute-phase and adaptive immune responses in vivo. J Virol 81, 1796-1812. Herweijer, H., and Wolff, J.A. (2007). Gene therapy progress and prospects: hydrodynamic gene delivery. Gene Ther 14, 99-107. Hohler, T., Kruger, A., Gerken, G., Schneider, P.M., Meyer zum Buschenefelde, K.H., and Rittner, C. (1998). A tumor necrosis factor-alpha (TNF-alpha) promoter polymorphism is associated with chronic hepatitis B infection. Clin Exp Immunol 111, 579-582. Hoofnagle, J.H. (1981). Serologic markers of hepatitis B virus infection. Annu Rev Med 32, 1-11. Hosel, M., Quasdorff, M., Wiegmann, K., Webb, D., Zedler, U., Broxtermann, M., Tedjokusumo, R., Esser, K., Arzberger, S., Kirschning, C.J., et al. (2009). Not interferon, but interleukin-6 controls early gene expression in hepatitis B virus infection. Hepatology 50, 1773-1782. Hsu, P.N., Yang, T.C., Kao, J.T., Cheng, K.S., Lee, Y.J., Wang, Y.M., Hsieh, C.T., Lin, C.W., and Wu, Y.Y. (2010). Increased PD-1 and decreased CD28 expression in chronic hepatitis B patients with advanced hepatocellular carcinoma. Liver Int 30, 1379-1386. Huang, L.R., Gabel, Y.A., Graf, S., Arzberger, S., Kurts, C., Heikenwalder, M., Knolle, P.A., and Protzer, U. (2012). Transfer of HBV genomes using low doses of adenovirus vectors leads to persistent infection in immune competent mice. Gastroenterology 142, 1447-1450 e1443. Huang, L.R., Wohlleber, D., Reisinger, F., Jenne, C.N., Cheng, R.L., Abdullah, Z., Schildberg, F.A., Odenthal, M., Dienes, H.P., van Rooijen, N., et al. (2013). Intrahepatic myeloid-cell aggregates enable local proliferation of CD8(+) T cells and successful immunotherapy against chronic viral liver infection. Nat Immunol 14, 574-583. Huang, L.R., Wu, H.L., Chen, P.J., and Chen, D.S. (2006). An immunocompetent mouse model for the tolerance of human chronic hepatitis B virus infection. Proc Natl Acad Sci U S A 103, 17862-17867. Huang, Y.H., Fang, C.C., Tsuneyama, K., Chou, H.Y., Pan, W.Y., Shih, Y.M., Wu, P.Y., Chen, Y., Leung, P.S., Gershwin, M.E., and Tao, M.H. (2011). A murine model of hepatitis B-associated hepatocellular carcinoma generated by adeno-associated virus-mediated gene delivery. Int J Oncol 39, 1511-1519. Hussain, M.J., Lau, J.Y., Williams, R., and Vergani, D. (1994). Hepatic expression of tumour necrosis factor-alpha in chronic hepatitis B virus infection. J Clin Pathol 47, 1112-1115. Iannacone, M., Sitia, G., Isogawa, M., Marchese, P., Castro, M.G., Lowenstein, P.R., Chisari, F.V., Ruggeri, Z.M., and Guidotti, L.G. (2005). Platelets mediate cytotoxic T lymphocyte-induced liver damage. Nat Med 11, 1167-1169. Ishida, Y., Agata, Y., Shibahara, K., and Honjo, T. (1992). Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. Embo J 11, 3887-3895. Iwai, Y., Terawaki, S., Ikegawa, M., Okazaki, T., and Honjo, T. (2003). PD-1 inhibits antiviral immunity at the effector phase in the liver. J Exp Med 198, 39-50. Jung, M.C., and Pape, G.R. (2002). Immunology of hepatitis B infection. Lancet Infect Dis 2, 43-50. Kajino, K., Jilbert, A.R., Saputelli, J., Aldrich, C.E., Cullen, J., and Mason, W.S. (1994). Woodchuck hepatitis virus infections: very rapid recovery after a prolonged viremia and infection of virtually every hepatocyte. J Virol 68, 5792-5803. Kann, M., Bischof, A., and Gerlich, W.H. (1997). In vitro model for the nuclear transport of the hepadnavirus genome. J Virol 71, 1310-1316. Kann, M., Sodeik, B., Vlachou, A., Gerlich, W.H., and Helenius, A. (1999). Phosphorylation-dependent binding of hepatitis B virus core particles to the nuclear pore complex. J Cell Biol 145, 45-55. Keasler, V.V., Hodgson, A.J., Madden, C.R., and Slagle, B.L. (2007). Enhancement of hepatitis B virus replication by the regulatory X protein in vitro and in vivo. J Virol 81, 2656-2662. Keng, V.W., Tschida, B.R., Bell, J.B., and Largaespada, D.A. (2011). Modeling hepatitis B virus X-induced hepatocellular carcinoma in mice with the Sleeping Beauty transposon system. Hepatology 53, 781-790. Kumar, M., Jung, S.Y., Hodgson, A.J., Madden, C.R., Qin, J., and Slagle, B.L. (2011). Hepatitis B virus regulatory HBx protein binds to adaptor protein IPS-1 and inhibits the activation of beta interferon. J Virol 85, 987-995. Lan, J.L., Chen, Y.M., Hsieh, T.Y., Chen, Y.H., Hsieh, C.W., Chen, D.Y., and Yang, S.S. (2011). Kinetics of viral loads and risk of hepatitis B virus reactivation in hepatitis B core antibody-positive rheumatoid arthritis patients undergoing anti-tumour necrosis factor alpha therapy. Ann Rheum Dis 70, 1719-1725. Lang, P.A., Lang, K.S., Xu, H.C., Grusdat, M., Parish, I.A., Recher, M., Elford, A.R., Dhanji, S., Shaabani, N., Tran, C.W., et al. (2012). Natural killer cell activation enhances immune pathology and promotes chronic infection by limiting CD8+ T-cell immunity. Proc Natl Acad Sci U S A 109, 1210-1215. Larrubia, J.R., Benito-Martinez, S., Miquel-Plaza, J., Sanz-de-Villalobos, E., Gonzalez-Mateos, F., and Parra, T. (2009). Cytokines - their pathogenic and therapeutic role in chronic viral hepatitis. Rev Esp Enferm Dig 101, 343-351. Lau, G.K., Suri, D., Liang, R., Rigopoulou, E.I., Thomas, M.G., Mullerova, I., Nanji, A., Yuen, S.T., Williams, R., and Naoumov, N.V. (2002). Resolution of chronic hepatitis B and anti-HBs seroconversion in humans by adoptive transfer of immunity to hepatitis B core antigen. Gastroenterology 122, 614-624. Le Duff, Y., Blanchet, M., and Sureau, C. (2009). The pre-S1 and antigenic loop infectivity determinants of the hepatitis B virus envelope proteins are functionally independent. J Virol 83, 12443-12451. Lin, Y.J., Huang, L.R., Yang, H.C., Tzeng, H.T., Hsu, P.N., Wu, H.L., Chen, P.J., and Chen, D.S. (2010). Hepatitis B virus core antigen determines viral persistence in a C57BL/6 mouse model. Proc Natl Acad Sci U S A 107, 9340-9345. Lin, Y.J., Wu, H.L., Chen, D.S., and Chen, P.J. (2012). Hepatitis B virus nucleocapsid but not free core antigen controls viral clearance in mice. J Virol 86, 9266-9273. Liu, F., Song, Y., and Liu, D. (1999). Hydrodynamics-based transfection in animals by systemic administration of plasmid DNA. Gene Ther 6, 1258-1266. Liu, Q., Zaiss, A.K., Colarusso, P., Patel, K., Haljan, G., Wickham, T.J., and Muruve, D.A. (2003). The role of capsid-endothelial interactions in the innate immune response to adenovirus vectors. Hum Gene Ther 14, 627-643. Lu, H.L., and Liao, F. (2013). Melanoma differentiation-associated gene 5 senses hepatitis B virus and activates innate immune signaling to suppress virus replication. J Immunol 191, 3264-3276. Lucifora, J., Durantel, D., Testoni, B., Hantz, O., Levrero, M., and Zoulim, F. (2010). Control of hepatitis B virus replication by innate response of HepaRG cells. Hepatology 51, 63-72. Lutgehetmann, M., Bornscheuer, T., Volz, T., Allweiss, L., Bockmann, J.H., Pollok, J.M., Lohse, A.W., Petersen, J., and Dandri, M. (2011). Hepatitis B virus limits response of human hepatocytes to interferon-alpha in chimeric mice. Gastroenterology 140, 2074-2083, 2083 e2071-2072. Maier, H., Isogawa, M., Freeman, G.J., and Chisari, F.V. (2007). PD-1:PD-L1 interactions contribute to the functional suppression of virus-specific CD8+ T lymphocytes in the liver. J Immunol 178, 2714-2720. Maini, M.K., Boni, C., Lee, C.K., Larrubia, J.R., Reignat, S., Ogg, G.S., King, A.S., Herberg, J., Gilson, R., Alisa, A., et al. (2000). The role of virus-specific CD8(+) cells in liver damage and viral control during persistent hepatitis B virus infection. J Exp Med 191, 1269-1280. Mingozzi, F., Liu, Y.L., Dobrzynski, E., Kaufhold, A., Liu, J.H., Wang, Y., Arruda, V.R., High, K.A., and Herzog, R.W. (2003). Induction of immune tolerance to coagulation factor IX antigen by in vivo hepatic gene transfer. J Clin Invest 111, 1347-1356. Mizuhara, H., O'Neill, E., Seki, N., Ogawa, T., Kusunoki, C., Otsuka, K., Satoh, S., Niwa, M., Senoh, H., and Fujiwara, H. (1994). T cell activation-associated hepatic injury: mediation by tumor necrosis factors and protection by interleukin 6. J Exp Med 179, 1529-1537. Moriyama, T., Guilhot, S., Klopchin, K., Moss, B., Pinkert, C.A., Palmiter, R.D., Brinster, R.L., Kanagawa, O., and Chisari, F.V. (1990). Immunobiology and pathogenesis of hepatocellular injury in hepatitis B virus transgenic mice. Science 248, 361-364. Neta, R., Oppenheim, J.J., and Douches, S.D. (1988). Interdependence of the radioprotective effects of human recombinant interleukin 1 alpha, tumor necrosis factor alpha, granulocyte colony-stimulating factor, and murine recombinant granulocyte-macrophage colony-stimulating factor. J Immunol 140, 108-111. Nurieva, R., Thomas, S., Nguyen, T., Martin-Orozco, N., Wang, Y., Kaja, M.K., Yu, X.Z., and Dong, C. (2006). T-cell tolerance or function is determined by combinatorial costimulatory signals. Embo J 25, 2623-2633. Oliviero, B., Varchetta, S., Paudice, E., Michelone, G., Zaramella, M., Mavilio, D., De Filippi, F., Bruno, S., and Mondelli, M.U. (2009). Natural killer cell functional dichotomy in chronic hepatitis B and chronic hepatitis C virus infections. Gastroenterology 137, 1151-1160, 1160 e1151-1157. Peng, G., Li, S., Wu, W., Sun, Z., Chen, Y., and Chen, Z. (2008a). Circulating CD4+ CD25+ regulatory T cells correlate with chronic hepatitis B infection. Immunology 123, 57-65. Peng, G., Li, S., Wu, W., Tan, X., Chen, Y., and Chen, Z. (2008b). PD-1 upregulation is associated with HBV-specific T cell dysfunction in chronic hepatitis B patients. Mol Immunol 45, 963-970. Peppa, D., Micco, L., Javaid, A., Kennedy, P.T., Schurich, A., Dunn, C., Pallant, C., Ellis, G., Khanna, P., Dusheiko, G., et al. (2010). Blockade of immunosuppressive cytokines restores NK cell antiviral function in chronic hepatitis B virus infection. PLoS Pathog 6, e1001227. Perez-Alvarez, R., Diaz-Lagares, C., Garcia-Hernandez, F., Lopez-Roses, L., Brito-Zeron, P., Perez-de-Lis, M., Retamozo, S., Bove, A., Bosch, X., Sanchez-Tapias, J.M., et al. (2011). Hepatitis B virus (HBV) reactivation in patients receiving tumor necrosis factor (TNF)-targeted therapy: analysis of 257 cases. Medicine (Baltimore) 90, 359-371. Pertel, T., Hausmann, S., Morger, D., Zuger, S., Guerra, J., Lascano, J., Reinhard, C., Santoni, F.A., Uchil, P.D., Chatel, L., et al. (2011). TRIM5 is an innate immune sensor for the retrovirus capsid lattice. Nature 472, 361-365. Rabe, B., Vlachou, A., Pante, N., Helenius, A., and Kann, M. (2003). Nuclear import of hepatitis B virus capsids and release of the viral genome. Proc Natl Acad Sci U S A 100, 9849-9854. Racanelli, V., and Rehermann, B. (2006a). The liver as an immunological organ. Hepatology 43, S54-62. Racanelli, V., and Rehermann, B. (2006b). The liver as an immunological organ. Hepatology 43, S54-S62. Racz, Z., Godo, M., Revesz, C., and Hamar, P. (2011). Immune activation and target organ damage are consequences of hydrodynamic treatment but not delivery of naked siRNAs in mice. Nucleic Acid Ther 21, 215-224. Rehermann, B., and Nascimbeni, M. (2005). Immunology of hepatitis B virus and hepatitis C virus infection. Nat Rev Immunol 5, 215-229. Ribeiro, R.M., Lo, A., and Perelson, A.S. (2002). Dynamics of hepatitis B virus infection. Microbes Infect 4, 829-835. Riu, E., Grimm, D., Huang, Z., and Kay, M.A. (2005). Increased maintenance and persistence of transgenes by excision of expression cassettes from plasmid sequences in vivo. Hum Gene Ther 16, 558-570. Roberts, L.R., and Gores, G.J. (2005). Hepatocellular carcinoma: molecular pathways and new therapeutic targets. Semin Liver Dis 25, 212-225. Roggendorf, M., Schulte, I., Xu, Y., and Lu, M. (2007). Therapeutic vaccination in chronic hepatitis B: preclinical studies in the woodchuck model. J Viral Hepat 14 Suppl 1, 51-57. Schildberg, F.A., Wojtalla, A., Siegmund, S.V., Endl, E., Diehl, L., Abdullah, Z., Kurts, C., and Knolle, P.A. (2011). Murine hepatic stellate cells veto CD8 T cell activation by a CD54-dependent mechanism. Hepatology 54, 262-272. Schmich, K., Schlatter, R., Corazza, N., Sa Ferreira, K., Ederer, M., Brunner, T., Borner, C., and Merfort, I. (2011). Tumor necrosis factor alpha sensitizes primary murine hepatocytes to Fas/CD95-induced apoptosis in a Bim- and Bid-dependent manner. Hepatology 53, 282-292. Shafritz, D.A. (2007). A human hepatocyte factory. Nat Biotechnol 25, 871-872. Shayakhmetov, D.M., Gaggar, A., Ni, S., Li, Z.Y., and Lieber, A. (2005). Adenovirus binding to blood factors results in liver cell infection and hepatotoxicity. J Virol 79, 7478-7491. Sitia, G., Iannacone, M., Muller, S., Bianchi, M.E., and Guidotti, L.G. (2007). Treatment with HMGB1 inhibitors diminishes CTL-induced liver disease in HBV transgenic mice. J Leukoc Biol 81, 100-107. Stacey, A.R., Norris, P.J., Qin, L., Haygreen, E.A., Taylor, E., Heitman, J., Lebedeva, M., DeCamp, A., Li, D., Grove, D., et al. (2009). Induction of a striking systemic cytokine cascade prior to peak viremia in acute human immunodeficiency virus type 1 infection, in contrast to more modest and delayed responses in acute hepatitis B and C virus infections. J Virol 83, 3719-3733. Stoop, J.N., van der Molen, R.G., Kuipers, E.J., Kusters, J.G., and Janssen, H.L. (2007a). Inhibition of viral replication reduces regulatory T cells and enhances the antiviral immune response in chronic hepatitis B. Virology 361, 141-148. Stoop, J.N., Woltman, A.M., Biesta, P.J., Kusters, J.G., Kuipers, E.J., Janssen, H.L., and van der Molen, R.G. (2007b). Tumor necrosis factor alpha inhibits the suppressive effect of regulatory T cells on the hepatitis B virus-specific immune response. Hepatology 46, 699-705. Stuyver, L., De Gendt, S., Van Geyt, C., Zoulim, F., Fried, M., Schinazi, R.F., and Rossau, R. (2000). A new genotype of hepatitis B virus: complete genome and phylogenetic relatedness. J Gen Virol 81, 67-74. Summers, J. (1981). Three recently described animal virus models for human hepatitis B virus. Hepatology 1, 179-183. Szkaradkiewicz, A., Jopek, A., Wysocki, J., Grzymislawski, M., Malecka, I., and Wozniak, A. (2003). HBcAg-specific cytokine production by CD4 T lymphocytes of children with acute and chronic hepatitis B. Virus Res 97, 127-133. Tedder, R.S., Ijaz, S., Gilbert, N., Barbara, J.A., Corden, S.A., Gilson, R.J., and Boxall, E.H. (2002). Evidence for a dynamic host-parasite relationship in e-negative hepatitis B carriers. J Med Virol 68, 505-512. Tuttleman, J.S., Pourcel, C., and Summers, J. (1986). Formation of the pool of covalently closed circular viral DNA in hepadnavirus-infected cells. Cell 47, 451-460. Tzeng, H.T., Tsai, H.F., Liao, H.J., Lin, Y.J., Chen, L., Chen, P.J., and Hsu, P.N. (2012). PD-1 blockage reverses immune dysfunction and hepatitis B viral persistence in a mouse animal model. PLoS One 7, e39179. Untergasser, A., Zedler, U., Langenkamp, A., Hosel, M., Quasdorff, M., Esser, K., Dienes, H.P., Tappertzhofen, B., Kolanus, W., and Protzer, U. (2006). Dendritic cells take up viral antigens but do not support the early steps of hepatitis B virus infection. Hepatology 43, 539-547. Velu, V., Titanji, K., Zhu, B., Husain, S., Pladevega, A., Lai, L., Vanderford, T.H., Chennareddi, L., Silvestri, G., Freeman, G.J., et al. (2009). Enhancing SIV-specific immunity in vivo by PD-1 blockade. Nature 458, 206-210. Visvanathan, K., Skinner, N.A., Thompson, A.J., Riordan, S.M., Sozzi, V., Edwards, R., Rodgers, S., Kurtovic, J., Chang, J., Lewin, S., et al. (2007). Regulation of Toll-like receptor-2 expression in chronic hepatitis B by the precore protein. Hepatology 45, 102-110. von Freyend, M.J., Untergasser, A., Arzberger, S., Oberwinkler, H., Drebber, U., Schirmacher, P., and Protzer, U. (2011). Sequential control of hepatitis B virus in a mouse model of acute, self-resolving hepatitis B. J Viral Hepat 18, 216-226. Waggoner, S.N., and Kumar, V. (2012). Evolving role of 2B4/CD244 in T and NK cell responses during virus infection. Front Immunol 3, 377. Waggoner, S.N., Taniguchi, R.T., Mathew, P.A., Kumar, V., and Welsh, R.M. (2010). Absence of mouse 2B4 promotes NK cell-mediated killing of activated CD8+ T cells, leading to prolonged viral persistence and altered pathogenesis. J Clin Invest 120, 1925-1938. Wang, H., and Ryu, W.S. (2010). Hepatitis B virus polymerase blocks pattern recognition receptor signaling via interaction with DDX3: implications for immune evasion. PLoS Pathog 6, e1000986. Webster, G.J., Reignat, S., Maini, M.K., Whalley, S.A., Ogg, G.S., King, A., Brown, D., Amlot, P.L., Williams, R., Vergani, D., et al. (2000). Incubation phase of acute hepatitis B in man: dynamic of cellular immune mechanisms. Hepatology 32, 1117-1124. Weinberger, K.M., Wiedenmann, E., Bohm, S., and Jilg, W. (2000). Sensitive and accurate quantitation of hepatitis B virus DNA using a kinetic fluorescence detection system (TaqMan PCR). J Virol Methods 85, 75-82. Wherry, E.J., Ha, S.J., Kaech, S.M., Haining, W.N., Sarkar, S., Kalia, V., Subramaniam, S., Blattman, J.N., Barber, D.L., and Ahmed, R. (2007). Molecular signature of CD8+ T cell exhaustion during chronic viral infection. Immunity 27, 670-684. Wieland, S., Thimme, R., Purcell, R.H., and Chisari, F.V. (2004). Genomic analysis of the host response to hepatitis B virus infection. Proc Natl Acad Sci U S A 101, 6669-6674. Wohlleber, D., Kashkar, H., Gartner, K., Frings, M.K., Odenthal, M., Hegenbarth, S., Borner, C., Arnold, B., Hammerling, G., Nieswandt, B., et al. (2012). TNF-induced target cell killing by CTL activated through cross-presentation. Cell Rep 2, 478-487. Wright, T.L., and Lau, J.Y. (1993). Clinical aspects of hepatitis B virus infection. Lancet 342, 1340-1344. Wu, J., Meng, Z., Jiang, M., Pei, R., Trippler, M., Broering, R., Bucchi, A., Sowa, J.P., Dittmer, U., Yang, D., et al. (2009). Hepatitis B virus suppresses toll-like receptor-mediated innate immune responses in murine parenchymal and nonparenchymal liver cells. Hepatology 49, 1132-1140. Xiang, X., Gui, H., King, N.J., Cole, L., Wang, H., Xie, Q., and Bao, S. (2012). IL-22 and non-ELR-CXC chemokine expression in chronic hepatitis B virus-infected liver. Immunol Cell Biol 90, 611-619. Xie, Z., Chen, Y., Zhao, S., Yang, Z., Yao, X., Guo, S., Yang, C., Fei, L., Zeng, X., Ni, B., and Wu, Y. (2009). Intrahepatic PD-1/PD-L1 up-regulation closely correlates with inflammation and virus replication in patients with chronic HBV infection. Immunol Invest 38, 624-638. Xu, D., Fu, J., Jin, L., Zhang, H., Zhou, C., Zou, Z., Zhao, J.M., Zhang, B., Shi, M., Ding, X., et al. (2006). Circulating and liver resident CD4+CD25+ regulatory T cells actively influence the antiviral immune response and disease progression in patients with hepatitis B. J Immunol 177, 739-747. Xu, L., Yin, W., Sun, R., Wei, H., and Tian, Z. (2013a). Kupffer cell-derived IL-10 plays a key role in maintaining humoral immune tolerance in HBV-persistent mice. Hepatology. Xu, L., Yin, W., Sun, R., Wei, H., and Tian, Z. (2013b). Kupffer cell-derived IL-10 plays a key role in maintaining humoral immune tolerance in hepatitis B virus-persistent mice. Hepatology. Xu, L., Yin, W., Sun, R., Wei, H., and Tian, Z. (2013c). Liver type I regulatory T cells suppress germinal center formation in HBV-tolerant mice. Proc Natl Acad Sci U S A 110, 16993-16998. Yan, H., Zhong, G., Xu, G., He, W., Jing, Z., Gao, Z., Huang, Y., Qi, Y., Peng, B., Wang, H., et al. (2012). Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus. Elife 1, e00049. Yang, P.L., Althage, A., Chung, J., and Chisari, F.V. (2002). Hydrodynamic injection of viral DNA: a mouse model of acute hepatitis B virus infection. Proc Natl Acad Sci U S A 99, 13825-13830. Yang, P.L., Althage, A., Chung, J., Maier, H., Wieland, S., Isogawa, M., and Chisari, F.V. (2010). Immune effectors required for hepatitis B virus clearance. Proc Natl Acad Sci U S A 107, 798-802. Yang, S.T., Yen, C.J., Lai, C.H., Lin, Y.J., Chang, K.C., Lee, J.C., Liu, Y.W., Chang-Liao, P.Y., Hsu, L.S., Chang, W.C., et al. (2013). SUMOylated CPAP is required for IKK-mediated NF-kappaB activation and enhances HBx-induced NF-kappaB signaling in HCC. J Hepatol 58, 1157-1164. Yin, W., Xu, L., Sun, R., Wei, H., and Tian, Z. (2012). Interleukin-15 suppresses hepatitis B virus replication via IFN-beta production in a C57BL/6 mouse model. Liver Int 32, 1306-1314. Yu, S., Chen, J., Wu, M., Chen, H., Kato, N., and Yuan, Z. (2010). Hepatitis B virus polymerase inhibits RIG-I- and Toll-like receptor 3-mediated beta interferon induction in human hepatocytes through interference with interferon regulatory factor 3 activation and dampening of the interaction between TBK1/IKKepsilon and DDX3. J Gen Virol 91, 2080-2090. Zhang, G., Ludtke, J.J., Thioudellet, C., Kleinpeter, P., Antoniou, M., Herweijer, H., Braun, S., and Wolff, J.A. (2004). Intraarterial delivery of naked plasmid DNA expressing full-length mouse dystrophin in the mdx mouse model of duchenne muscular dystrophy. Hum Gene Ther 15, 770-782. Zhang, J.Y., Zhang, Z., Lin, F., Zou, Z.S., Xu, R.N., Jin, L., Fu, J.L., Shi, F., Shi, M., Wang, H.F., and Wang, F.S. (2010). Interleukin-17-producing CD4(+) T cells increase with severity of liver damage in patients with chronic hepatitis B. Hepatology 51, 81-91. Zhang, Z., Jin, B., Zhang, J.Y., Xu, B., Wang, H., Shi, M., Wherry, E.J., Lau, G.K., and Wang, F.S. (2009). Dynamic decrease in PD-1 expres | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/5462 | - |
dc.description.abstract | B型肝炎持續性感染會造成慢性肝炎,肝纖維化和肝癌。近來在動物模式中研究病毒感染的報告指出淋巴球上的抑制性受體 (PD-1) 和配體 (PD-L1) 間的相互作用對於抑制T細胞的活性扮演重要角色。我們利用最近發展的B型肝炎小鼠模式來探討T細胞exhaustion現象及阻斷PD-1/PD-L1作用後對於肝浸潤T細胞的效應。在此小鼠模式中,我們證明了B型肝炎的持續性和肝浸潤T細胞的PD-1表現成正相關,在帶原小鼠中肝浸潤CD8 T細胞表現較高的PD-1和較低的CD127 exhaustion現象,並且利用單株抗體阻斷PD-1/PD-L1作用可增加病毒核心蛋白專一性的IFN-γ產生,而且可以反轉T淋巴球的exhaustion及增加小鼠對病毒的清除能力。我們的結果指出,在小鼠模式中阻斷PD-1的途徑可恢復對B肝病毒的免疫反應及增進對病毒的清除。
先天與後天免疫反應的調和才能有效的控制病毒感染,為了瞭解對抗B肝病毒的先天免疫反應,我們使用了一系列與先天免疫反應相關受體之基因缺陷小鼠來測試,結果發現除了腫瘤壞死因子缺失的小鼠外,其餘包括IFN-α/β receptor, RIG-I, MDA5, MYD88, NLRP3, ASC, 和 IL-1R基因缺失小鼠都與控制組相當。我們進一步發現,給予小鼠腫瘤壞死因子受體阻斷劑可促使CD8 T細胞PD-1表現、肝臟中病毒複製、核心抗原和表面抗原及血清病毒量增加;純化後的病毒核心蛋白可在小鼠引發腫瘤壞死因子及IL-6表現,但IFN-β則否。我們也發現病毒核心蛋白造成肝臟中白血球引發的腫瘤壞死因子是清除病毒的重要途徑,這些結果提供了腫瘤壞死因子相關的先天免疫反應對抗病毒的機制,也解釋了臨床上使用腫瘤壞死因子阻斷劑造成B肝病毒再活化的機制。 | zh_TW |
dc.description.abstract | Persistent hepatitis B viral (HBV) infection results in chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma (HCC). Recent studies in animal models of viral infection indicate that the interaction between the inhibitory receptor, programmed death (PD)-1, on lymphocytes and its ligand (PD-L1) play a critical role in T-cell exhaustion by inducing T-cell inactivation. We studied T-cell exhaustion and the effects of PD-1 and PD-L1 blockade on intrahepatic infiltrating T-cells in our recently developed mouse model of HBV persistence. In this mouse animal model, we demonstrated that the chronicity of hepatitis B virus infection was associated with PD-1 expression on intrahepatic lymphocytes. The Intrahepatic CD8+ T-cells expressed higher levels of PD-1 and lower levels of CD127 in carrier mice. Blockade of PD-1/PD-L1 interactions by an anti-PD-1 monoclonal antibody (mAb) increased HBcAg-specific interferon (IFN)-γ production in intrahepatic T lymphocytes and reversed the exhausted phenotype in intrahepatic T lymphocytes and viral persistence to clearance of HBV in vivo. Our results indicated that PD-1 blockage reverses immune dysfunction and viral persistence of HBV infection in a mouse animal model, suggesting that the anti-PD-1 mAb might be a good therapeutic candidate for chronic HBV infection.
An efficient control of virus infections requires the coordinated actions of both innate and adaptive immune responses. In order to define the role of innate immunity effectors against HBV, viral clearance was studied in a panel of immunodeficient mouse strains. Our results demonstrate that HBV viral clearance is not changed in IFN-α/β receptor (IFNAR), RIG-I, MDA5, MYD88, NLRP3, ASC, and IL-1R knockout mice. In contrast, HBV persists in the absence of tumor necrosis factor-alpha (TNF-α) or in mice treated with the soluble TNF receptor blocker, Etanercept. In these mice, there was an increase in PD-1-expressing CD8+ T-cells and an increase of serum HBV DNA, HBV core, and surface antigen expression as well as viral replication within the liver. Furthermore, the induction of TNF-α in clearing HBV is dependent on the HBV core, and TNF blockage eliminated HBV core-induced viral clearance effects. Finally, the intra-hepatic leukocytes (IHLs), but not the hepatocytes, are the cell source responsible for TNF-α production induced by HBcAg. These results provide evidences for TNF-α mediated innate immune mechanisms in HBV clearance and explain the mechanism of HBV reactivation during therapy with TNF blockage agents. | en |
dc.description.provenance | Made available in DSpace on 2021-05-15T17:59:35Z (GMT). No. of bitstreams: 1 ntu-103-D96449003-1.pdf: 2489548 bytes, checksum: 3282d05fd438da29dbe7b2e8d6ebd766 (MD5) Previous issue date: 2014 | en |
dc.description.tableofcontents | 中文摘要 - - - - - - - - - - - - - - - - - - - - - - - - - - - i
Abstract - - - - - - - - - - - - - - - - - - - - - - - - - - - ii Table of Contents- - - - - - - - - - - - - - - - - - - - - - - iv Abbreviations- - - - - - - - - - - - - - - - - - - - - - - - - x Chapter I: Introduction- - - - - - - - - - - - - - - - - - - - 1 1.1 Virology of Hepatitis B virus - - - - - - - - - - - - - - - - - 2 1.2 Natural history of Hepatitis B virus infection - - - - - - - - - - 3 1.3 Immune-mediated pathogenesis of Hepatitis B- - - - - - - - - - -5 1.3.1 Adaptive immunity against HBV - - - - - - - - - - - - - - - - 5 1.3.2 Innate immunity against HBV- - - - - - - - - - - - - - - - - -8 1.4 Animal models for exploring immune mechanism of hepatitis B - - - 9 1.4.1 Hydrodynamic-based transfection of HBV mouse model - - - - - - 11 1.4.2 HBV mouse model generated by delivery of adenovirus- - - - - - - 14 1.4.3 Adeno-associated viral vectors (AAV)-based HBV mouse model- - - -16 1.4.4 Comparison of the advantages and disadvantages in each model- - - - 16 Chapter II: Materials and Methods - - - - - - - - - - - - - - - 19 2.1 Animals and HBV constructs- - - - - - - - - - - - - - - - - - 20 2.2 Hydrodynamic injection- - - - - - - - - - - - - - - - - - - - 20 2.3 Isolation of intrahepatic leukocytes- - - - - - - - - - - - - - - -21 2.4 Isolation of primary hepatocytes - - - - - - - - - - - - - - - - 22 2.5 Detection of the HBV antigen, antibody (Ab), and DNA- - - - - - -22 2.6 Liver tissue preparation and immunoblotting- - - - - - - - - - - 23 2.7 Immunohistochemistry - - - - - - - - - - - - - - - - - - - - 24 2.8 Interferon (IFN)-γ enzyme-linked immunospot (ELISpot) assay - - - 25 2.9 Flow cytometry- - - - - - - - - - - - - - - - - - - - - - - -25 2.10 Co-culture assay- - - - - - - - - - - - - - - - - - - - - - -26 2.11 In vivo treatment of mice with the anti-PD-1 mAb- - - - - - - - -26 2.12 Purification of monoclonal antibody from hybridoma - - - - - - -27 Chapter III: Results - - - - - - - - - - - - - - - - - - - - - -28 3.1 Inhibitory receptor PD-1 in chronic viral infection - - - - - - - - -29 3.2 Increased PD-1-expressing CD8+ and CD4+ T-cells in liver-infiltrating lymphocytes from mice with HBV persistence- - - -30 3.3 Liver-infiltrating CD8+ lymphocytes in carrier mice displayed the PD-1hiCD127low-exhausted phenotype - - - - - - - - - - - - - - 32 3.4 Liver-infiltrating PD-1+CD4+ T-cells in mice with HBV persistence exhibit the phenotype of regulatory T-cells (Tregs) - - - - - - - - - - - - --33 3.5 Blockade of the PD-1 pathway by an anti-PD-1 mAb reduced the HBV persistence rate in this mouse animal model- - - - - - - - - 34 3.6 Induction of host innate immune response by HBV - - - - - - - - 36 3.7 The TNF-α rather than IFN-mediated pathway is critical in HBV clearance- - - - - - - - - - - - - - - - - - - - - - - - - - 38 3.8 TNF-α deficiency leads to cytotoxic T lymphocyte dysfunction against HBV- - - - - - - - - - - - - - - - - - - - - - - - -40 3.9 TNF-α blockage-induced elevation of serum HBV viral loads and maintained HBV viral gene expression within the liver - - - - - - - - - - - -41 3.10 Lack of TNF-α eliminates HBcAg-induced HBsAg clearance- - - - 43 3.11 Intra-hepatic leukocytes, in contrasting with HBcAg containing hepatocytes, were responsible for HBcAg-induced TNF-α production- - - - - - -44 Chapter IV: Discussion - - - - - - - - - - - - - - - - - - - - -47 4.1 Immune suppression of intrahepatic T lymphocytes in hydrodynamic-based transfection of HBV persistence mouse model- - 48 4.2 Antiviral response of intrahepatic T-cell can be restored by blocking PD-1 pathway in vivo - - - - - - - - - - - - - - - - - - - - - - - 51 4.3 TNF-α contributes to induce an effective T cell response and lead to HBV clearance - - - - - - - - - - - - - - - - - - - - - - - - - - 54 4.4 Intact structure of HBcAg is critical for triggering innate immune response - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -57 4.5 IFN-mediated pathways are not required for HBV clearance in vivo- - 61 4.6 Working hypothesis of HBV-induced immunity in this mouse model - -62 References - - - - - - - - - - - - - - - - - - - - - - - - - - - 65 List of Figures - - - - - - - - - - - - - - - - - - - - - - - - - -82 Figure 1. Increased programmed death (PD)-1-expressing CD8+ and CD4+ T-cells in liver-infiltrating lymphocytes from mice with hepatitis B viral (HBV) persistence- - - - - - - - - - - - - - - - - - - - - - - - - - - -84 Figure 2. Hepatitis B viral (HBV) core mutants induced upregulation of programmed death (PD)-1 expression in intrahepatic T lymphocytes - - -86 Figure 3. Liver-infiltrating CD8+ lymphocytes in carrier mice displayed the PD-1hiCD127low-exhausted phenotype- - - - - - - - - - - - - - - - 87 Figure 4. Liver-infiltrating PD-1+CD4+ T-cells in mice with hepatitis B viral (HBV) persistence exhibited the phenotype of regulatory T-cells- - - - - - - - 88 Figure 5. Impaired HBcAg-specific interferon (IFN)-γ production in C57BL/6 mice with hepatitis B viral (HBV) persistence was reversed by treatment of mice with anti-PD-1 mAb- - - - - - - - - - - - - - - - - - - - - - - - - -90 Figure 6. Blockade of the programmed death (PD)-1 pathway by an anti-PD-1 monoclonal antibody (mAb) reduced the hepatitis B viral (HBV) persistence rate in a mouse animal model- - - - - - - - - - - - - - - - - - - - - 91 Figure 7. Increased CD127 expression and reversed PD-1hiCD127low-exhausted CD8+ T cells phenotype in mice treated with an anti-PD-1 mAb- - - - - 92 Figure 8. Prolonged HBV persistence in TNF-α knockout mice - - - - - 93 Figure 9. Delayed HBsAg clearance in mice with TNF deficiency - - - - 95 Figure 10. Liver-infiltrating CD8+ lymphocytes in Etanercept-treated and TNF-α knockout mice displayed the PD-1hiCD127low-exhausted phenotype and impaired HBcAg-specific IFN-γ T cell response - - - - - - - - - - - - - - - -96 Figure 11. Delayed clearance of serum HBV DNA in mice with TNF deficiency - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -98 Figure 12. Decreased HBV replication and viral gene expression in Etanercept-treated and TNF-α knockout mice after pAAV/HBV1.2 injection- - - - - - - - - - - - - - - - - - - - - -99 Frigure 13. Hepatitis B viral core capsid triggered innate cytokines production in vivo - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 101 Figure 14. Intact HBV core capsid structure was required for innate cytokines induction - - - - - - - - - - - - - - - - - - - - - - - - - - - -102 Figure 15. A lack of TNF-α abolished HBcAg-induced HBsAg clearance in mice sera - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 103 Figure 16. Single dose administration of Enbrel at day 3 postinjection prolonged HBV persistence effectively- - - - - - - - - - - - - - - - - - - - -105 Figure 17. Intra hepatic leukocytes were responsible for HBcAg-induced TNF-α production in an ex vivo culture system- - - - - - - - - - - - - - - -106 Figure 18. Working hypothesis of HBV-induced immunity in this mouse model - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 108 Table 1 Characteristics of mice animal model for studying immune responses toward HBV- - - - - - - - - - - - - - - - - - - - - - - - - - - 109 Appendix - - - - - - - - - - - - - - - - - - - - - - - - - - - - 110 Figure A1. No significant difference in HBsAg clearance between wildtype C57BL/6 and IFNAR knockout mice- - - - - - - - - - - - - - - - - 111 Figure A2. Analysis of the induction kinetics of HBV-responsive genes- - 112 Figure A3. RIG-I-like receptor was critical for HBV core protein-induced IRF3 activation - - - - - - - - - - - - - - - - - - - - - - - - - - - - 113 Figure A4. Association of MDA5 and HBV core antigen was dependent on viral capsid structure- - - - - - - - - - - - - - - - - - - - - - - - - -115 | |
dc.language.iso | en | |
dc.title | 以B型肝炎病毒小鼠模式探討核心蛋白引發免疫反應之機制 | zh_TW |
dc.title | Induction of Immune Response by Hepatitis B virus Core Protein in a Mouse Model | en |
dc.type | Thesis | |
dc.date.schoolyear | 102-1 | |
dc.description.degree | 博士 | |
dc.contributor.oralexamcommittee | 陳培哲,謝世良,司徒惠康,陳俊任 | |
dc.subject.keyword | B型肝炎病毒,PD-1阻斷,病毒持續性,先天免疫力,腫瘤壞死因子, | zh_TW |
dc.subject.keyword | Hepatitis B virus,PD-1 blockage,viral persistence,innate immunity,Tumor necrosis factor, | en |
dc.relation.page | 116 | |
dc.rights.note | 同意授權(全球公開) | |
dc.date.accepted | 2014-02-11 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 免疫學研究所 | zh_TW |
顯示於系所單位: | 免疫學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-103-1.pdf | 2.43 MB | Adobe PDF | 檢視/開啟 |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。